Credit Suisse disclosed Shire PLC (LON:SHP), supporting its price target at 5,200.00GBX earlier today
- Updated: October 7, 2016
Reporting a potential upside of 0.02%, Credit Suisse hold steady the price target of Shire PLC (LON:SHP) at 5,200.00GBX
Yesterday Shire PLC (LON:SHP) traded 1.60% higher at 5,080.00GBX. The company’s 50-day moving average is 4,985.70GBX and its 200-day moving average is 4,560.67GBX. The last closing price is up 13.93% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 2,389,832 shares of the stock were exchanged, up from an average trading volume of 1,897,140
See Chart Below
Shire PLC has a 52 week low of 2,707.19GBX and a 52 week high of 5,377.00GBX with a P/E ratio of 32.39 The company’s market cap is currently 0 GBX.
In addition to Credit Suisse reporting its target price, a total of 18 brokers have issued a report on the stock. The consensus target price is 73.73GBX with 6 brokers rating the stock a strong buy, 16 brokers rating the stock a buy, 0 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.
General Information About Shire PLC (LON:SHP)
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. The Company's products include VYVANSE/VENVANSE/ELVANSE/TYVENSE/ELVANSEVUXEN/ADUVANZ (lisdexamfetamine dimesylate), ADDERALL XR (mixed salts of a single-entity amphetamine), INTUNIV (extended release guanfacine), LIALDA (mesalamine)/MEZAVANT(mesalazine), PENTASA (mesalamine), REPLAGAL (agalsidase alfa), ELAPRASE (idursulfase), VPRIV (velaglucerase alfa), FIRAZYR (icatibant), FOSRENOL (lanthanum carbonate), KALBITOR, CINRYZE C1 esterase inhibitor (human), GATTEX/REVESTIVE, BUMINATE 25% Albumin (Human), BUMINATE 5% Albumin (Human), GLASSIA Alpha1-Proteinase Inhibitor (Human) and ONCASPAR pegaspargase.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.